Otonomy, a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, has appointed Gerald Wroblewski as the company's chief operations officer.  The company has plans to initiate a phase II study for its lead drug candidate, OTO-104, in patients with Meniere's disease and is also positioned to begin clinical trials of a second product candidate, OTO-201, by the end of 2011.

Prior to joining Otonomy, Wroblewski served as vice president of operations at MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions.  Before his work with MacuSight, he was chief operating officer at iScience Interventional and executive vice president of operations at Oculex Pharmaceuticals.